💊 Weak Opioids (Codeine, Tramadol)

Weak opioids are a class of analgesic drugs used for moderate pain relief. They act on opioid receptors but have a lower affinity or intrinsic activity compared to strong opioids, or require metabolic activation.

Codeine is a prodrug that is metabolised to morphine via CYP2D6, which then acts as an agonist at mu-opioid receptors. Tramadol has a dual mechanism, acting as a weak mu-opioid receptor agonist and also inhibiting the reuptake of noradrenaline and serotonin, contributing to its analgesic effect.

These drugs are indicated for the management of moderate pain when non-opioid analgesics alone are insufficient. Codeine is also used as an antitussive for dry cough. Tramadol can be useful for neuropathic pain components due to its noradrenergic and serotonergic effects.

Contraindications include hypersensitivity to the drug, acute respiratory depression, and acute alcoholism. Codeine is contraindicated in children under 12 years and in breastfeeding mothers due to the risk of ultra-rapid metabolism. Tramadol should be avoided in patients with a history of epilepsy or those on MAOIs.

Common adverse effects include nausea, vomiting, constipation, dizziness, and drowsiness. Respiratory depression is a serious but less common side effect, especially with codeine in ultra-rapid metabolizers. Tramadol can lower the seizure threshold and carries a risk of serotonin syndrome when combined with other serotonergic drugs.

Patients should be monitored for signs of respiratory depression, especially at initiation or dose escalation. Bowel function should be monitored due to the risk of constipation. In patients with renal or hepatic impairment, dose adjustments and closer monitoring for adverse effects are necessary.

Always check for other CNS depressants or serotonergic drugs the patient may be taking. Counsel on potential for drowsiness, constipation, and the risk of dependence with prolonged use. Advise against driving or operating machinery until effects are known. Enquire about history of seizures or substance misuse.

Understanding the metabolism of codeine and its implications for efficacy and safety is crucial. Tramadol's unique mechanism and its risks (seizures, serotonin syndrome) are high-yield. These drugs represent a step-up from paracetamol/NSAIDs in the analgesic ladder for moderate pain.

SBAs frequently test the prodrug nature of codeine and the implications of CYP2D6 polymorphism (ultra-rapid metabolizers). Questions on tramadol often focus on its dual mechanism, risk of serotonin syndrome, and seizure threshold lowering. Differentiating their use from strong opioids is also common.